934542-76-4 (5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid,5-[3-(ethylsulfonyl)phenyl]-4,8-dimethyl-9h-pyrido[2,3-b]indole-7 -carboxylic Acid)

CAS号:
934542-76-4
中文名称:
5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid
英文名称:
5-[3-(ethylsulfonyl)phenyl]-4,8-dimethyl-9h-pyrido[2,3-b]indole-7 -carboxylic Acid
分子式:
C22H20N2O4S
分子量:
408.470204353333

5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid(934542-76-4)名称与标识符

名称

中文别名:
5-(3-(乙基磺酰基)苯基)-4,8-二甲基-9h-吡啶并[2,3-b]吲哚-7-羧酸;
英文别名:
5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid;SureCN725001;5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-9H-pyrido[2,3-b]indole-7-carboxylicacid;5-[3-(Bromomethyl)phenyl]-3-methyl-1,2,4-oxadiazol;5-[3-(ethylsulfonyl)phenyl]-3,8-dimethyl-9H-pyrido[2,3-b]indole-7-carboxylic acid;PubChem23332;SBB101218;3-(3-Methyl-1,2,4-oxadiazol-5-yl)benzyl bromide;5-[3-(diethylaminomethyl)-1-octyl-1H-indol-5-yl]pyrimidin-2-amine;CTK3I6433;5-[3-(bromomethyl)phenyl]-3-methyl-1,2,4-oxadizole;5-(3-diethylaminomethyl-1-octyl-1H-indol-5-yl)pyrimidin-2-ylamine;5-(3-(ETHYLSULFONYL)PHENYL)-4,8-DIMETHYL-9H-PYRIDO[2,3-B]INDOLE-7-CARBOXYLIC ACID;5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-9H-pyrido[2,3-b]indole-7-carboxylic acid (ACI);

标识符

MDL:
MFCD32876807
InChIKey:
GYVKQSOJRVOTQA-UHFFFAOYSA-N
Inchi:
1S/C22H20N2O4S/c1-4-29(27,28)15-7-5-6-14(9-15)17-10-16(22(25)26)13(3)20-19(17)18-8-12(2)11-23-21(18)24-20/h5-11H,4H2,1-3H3,(H,23,24)(H,25,26)
SMILES:
O=C(C1C(C)=C2C(C3C(N2)=NC=C(C)C=3)=C(C2C=C(S(CC)(=O)=O)C=CC=2)C=1)O

5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid(934542-76-4)物化性质

计算特性

  • 氢键供体数量 : 2
  • 氢键受体数量 : 6
  • 可旋转化学键数量 : 4
  • 重原子数量 : 29

5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid(934542-76-4)推荐厂家 更多厂家(3)

公司名称手机号/电话联系人QQ微信询单
上海绩祥生物科技有限公司 13093077543陆经理 3985448220
询单
江苏艾康生物医药研发有限公司 18795912720
025-66061636
杨情情 3004779232
询单
上海吉至生化科技有限公司 18117592386
021-57481218
吉至试剂 3007522982
询单
上海源叶生物科技有限公司 15026964105
15026964105
汤思磊 2881489226
询单

5-[3-(Ethylsulfonyl)phenyl]-4,8-dimethyl-9H-pyrido[2,3-b]indole-7 -carboxylic acid(934542-76-4)合成路线

合成路线:1 步
反应条件:
参考文献:
Preparation of pyridoindoles as kinase inhibitors
, United States, , ,
合成路线:1 步
反应条件:
参考文献:
Pyrido[2,3-b]indole derivatives as kinase inhibitors and their preparation and use in the treatment of diseases
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide for disease treatment
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of pyridoindoles as kinase inhibiting compounds for treating and preventing kinase-associated diseases
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of α-carbolines via palladium-catalyzed cyclization of diarylamines.
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Integrated Cross-Coupling Strategy for an α-Carboline-Based Aurora B Kinase Inhibitor
Mineno, Masahiro; Sera, Misayo; Ueda, Tsuyoshi; Mizufune, Hideya; Zanka, Atsuhiko; et al, Journal of Organic Chemistry, 2015, 80(3), 1564-1568
合成路线:1 步
反应条件:
参考文献:
Integrated Pd-catalyzed cross-coupling strategies for furnishing α-carbolines
Sera, Misayo; Mizufune, Hideya; Ueda, Tsuyoshi; Mineno, Masahiro; Zanka, Atsuhiko, Tetrahedron, 2017, 73(40), 5946-5958
合成路线:1 步
参考文献:
Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
, United States, , ,
合成路线:1 步
参考文献:
Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide to treat a diseases involving kinase activity
, World Intellectual Property Organization, , ,
合成路线:1 步
参考文献:
Preparation of pyridoindoles as kinase inhibiting compounds for treating and preventing kinase-associated diseases
, World Intellectual Property Organization, , ,